Journal
Journal
GU Oncology Now Journal
Daniel Tennenbaum, MDJournal | November 22, 2022
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
Read More
Akhil Abraham Saji, MDJournal | November 22, 2022
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
Akhil Abraham Saji, MDJournal | November 22, 2022
1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine.
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
David Ambinder, MDJournal | November 22, 2022
Robert Uzzo gives an overview of the RENAL score that he developed, plus his outlook on the future of renal characterization.
Akhil Abraham Saji, MDJournal | November 22, 2022
The history of robot-assisted laparoscopic & open radical prostatectomies are discussed with their outcomes and future uses.
David Ambinder, MDJournal | November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
Linda Brookes, MScJournal | November 22, 2022
Bradley McGregor, MD gives an overview of his GU oncology career from his Air Force beginnings to his work at Dana-Farber.
Catherine H. Marshall, MD, MPHJournal | November 22, 2022
Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer.
David Ambinder, MDJournal | October 24, 2022
A review of “A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers” from the CKCis.
Daniel Tennenbaum, MDJournal | October 24, 2022
A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management.
Akhil Abraham Saji, MDJournal | October 24, 2022
Integrated imaging with PET/CT has allowed clinicians to gain significant anatomical and oncologic information on tumors.
Akhil Abraham Saji, MDJournal | October 24, 2022
Abiraterone acetate + prednisolone is compared to enzalutamide + AAP for mHSPC cancer starting androgen-deprivation therapy.
Akhil Abraham Saji, MDJournal | October 24, 2022
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
David Ambinder, MDJournal | October 24, 2022
Scott Eggener, MD gives an overview of focal therapy for prostate cancer, including its benefits and current research.
David Ambinder, MDJournal | October 24, 2022
Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG.
Linda Brookes, MScJournal | October 24, 2022
Dr. Preston C. Sprenkle, MD discusses his career beginnings in urology and interest in prostate ablation therapy research.
GU Oncology Now EditorsJournal | October 24, 2022
Cell-based therapies have shown efficacy in disease settings, but for solid tumors, research has proceeded at a slower pace.
Akhil Abraham Saji, MDJournal | September 27, 2022
Socioeconomic disadvantages, disparities, and equitable access in kidney and bladder cancer care are reviewed.
David Ambinder, MDJournal | September 27, 2022
According to a recent study, laparoscopic surgery may be equivalent to open surgery for performing partial nephrectomies.
Advertisement
Advertisement